FDA Accepts NDA of BI’s and Eli Lilly’s Combination Diabetes DrugBy
Empagliflozin is a sodium glucose co-transporter-2 inhibitor, which removes excess glucose through the urine by blocking glucose reabsorption in the kidney. Metformin, a commonly prescribed initial treatment for Type II diabetes, decreases the production of glucose in the liver and its absorption in the intestine and improves the body’s ability to utilize glucose.
Empagliflozin, marketed as Jardiance (empagliflozin) tablets in the US was approved by the
Source: Eli Lilly